JP2019534317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534317A5 JP2019534317A5 JP2019533260A JP2019533260A JP2019534317A5 JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5 JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- amino acid
- purified
- proteinaceous molecule
- lsd1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903602 | 2016-09-07 | ||
| AU2016903602A AU2016903602A0 (en) | 2016-09-07 | Inhibitors and uses therefor | |
| PCT/AU2017/050969 WO2018045422A1 (en) | 2016-09-07 | 2017-09-07 | Lysine specific histone demethylase-1 inhibitors and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534317A JP2019534317A (ja) | 2019-11-28 |
| JP2019534317A5 true JP2019534317A5 (https=) | 2021-03-04 |
Family
ID=61561256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533260A Pending JP2019534317A (ja) | 2016-09-07 | 2017-09-07 | リジン特異的ヒストンデメチラーゼ−１阻害剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220040280A1 (https=) |
| EP (1) | EP3509627A4 (https=) |
| JP (1) | JP2019534317A (https=) |
| CN (1) | CN110312522A (https=) |
| AU (1) | AU2017323868A1 (https=) |
| CA (1) | CA3035806A1 (https=) |
| SG (1) | SG11201901624RA (https=) |
| WO (1) | WO2018045422A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102095104B1 (ko) * | 2018-04-24 | 2020-04-23 | 서울대학교산학협력단 | PKCα-LSD1-NFκB 경로를 표적으로 하는 염증반응 조절제 스크리닝 방법용도 |
| EP3636284A1 (en) * | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
| CA3149964A1 (en) | 2019-09-03 | 2021-03-11 | Michelle Wykes | Methods and agents for determining patient status |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| US20240418723A1 (en) * | 2021-10-20 | 2024-12-19 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE554184T1 (de) * | 2004-12-16 | 2012-05-15 | Harvard College | Durch das nukleäre aminoxidase-homolog lsd1 vermittelte histondemethylierung |
| US7858395B2 (en) * | 2005-07-13 | 2010-12-28 | Universitaetsklinikum Freiburg | Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US20120108500A1 (en) * | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| EP3789405A1 (en) * | 2012-10-12 | 2021-03-10 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
| CA2916533C (en) * | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| US9186391B2 (en) * | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| CA2958704A1 (en) * | 2014-08-25 | 2016-03-03 | University Of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| AU2016382512A1 (en) * | 2015-12-30 | 2018-07-12 | Novartis Ag | Immune effector cell therapies with enhanced efficacy |
-
2017
- 2017-09-07 CA CA3035806A patent/CA3035806A1/en active Pending
- 2017-09-07 WO PCT/AU2017/050969 patent/WO2018045422A1/en not_active Ceased
- 2017-09-07 JP JP2019533260A patent/JP2019534317A/ja active Pending
- 2017-09-07 AU AU2017323868A patent/AU2017323868A1/en not_active Abandoned
- 2017-09-07 SG SG11201901624RA patent/SG11201901624RA/en unknown
- 2017-09-07 CN CN201780068891.6A patent/CN110312522A/zh active Pending
- 2017-09-07 US US16/330,628 patent/US20220040280A1/en not_active Abandoned
- 2017-09-07 EP EP17847815.2A patent/EP3509627A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534317A5 (https=) | ||
| Zhou et al. | Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant | |
| Buffalo et al. | How HIV Nef proteins hijack membrane traffic to promote infection | |
| Zhang et al. | Human T-cell lymphotropic virus type 1 and its oncogenesis | |
| Verhelst et al. | Mx proteins: antiviral gatekeepers that restrain the uninvited | |
| SG181523A1 (en) | Therapeutic compounds and related methods of use | |
| RU2495044C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| Ohkoshi et al. | Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy | |
| EA027040B1 (ru) | Модулирующие иммуносупрессию соединения | |
| JP2016515561A5 (https=) | ||
| EA200900184A1 (ru) | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации | |
| CA2787309A1 (en) | Hepatitis c virus inhibitors | |
| Suprunenko et al. | Complexities of type I interferon biology: lessons from LCMV | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| CN101631780A (zh) | 用于抗病毒治疗的吩噻嗪衍生物 | |
| Stott et al. | Distinct molecular mechanisms of host immune response modulation by arenavirus NP and Z proteins | |
| CA3198757A1 (en) | Aromatic boron-containing compounds and insulin analogs | |
| Lara-Urena et al. | Relevance of BET family proteins in SARS-CoV-2 infection | |
| RU2018142174A (ru) | Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения | |
| US7604804B2 (en) | Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120 | |
| AU2018269937A1 (en) | Methods for modifying endoplasmic reticulum processing of protein | |
| JP2019505210A5 (https=) | ||
| RU2018126487A (ru) | Противораковые вакцины | |
| RU2011120447A (ru) | Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины | |
| US10093699B2 (en) | Peptides with antimicrobial, anticancer and/or wound-healing promoting activities, pharmaceutical compositions containing the same, and use of the peptides with antimicrobial, anticancer and/or wound-healing promoting activities |